Trulicity is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of Trulicity and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
https://www.drugs.com/pro/trulicity.html
Patient/Family Teaching. 1  Instruct patient on use of pen and to take dulaglutide as directed. Follow manufacturer's instructions for pen use. 2  Take missed dose as soon as remembered as long as 3 days (72 hr) until next scheduled dose. If less than 3 days until next scheduled dose, skip and take next scheduled dose.
http://medical-dictionary.thefreedictionary.com/Trulicity
Dosage Modifications. Renal impairment (any severity): No dosage adjustment required. Dosing Considerations. Coadministration with insulin secretagogues (eg, sulfonylureas) or insulin: When initiating dulaglutide, consider reducing the dosage of concomitantly administered insulin or insulin secretagogues to reduce risk of hypoglycemia.
http://reference.medscape.com/drug/trulicity-dulaglutide-999965
Trulicity❅ 0.75 mg solution for injection in pre-filled pen. Trulicity 1.5 mg solution for injection in pre-filled pen. Trulicity 0.75 mg solution for injection in pre-filled syringe. Trulicity 1.5 mg solution for injection in pre-filled syringe.
http://www.medicines.org.uk/emc/medicine/29747
Food and Drug Administration today approved Trulicity (dulaglutide), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.
http://medical-dictionary.thefreedictionary.com/Trulicity
Trulicity (dulaglutide) is a human GLP-1 receptor agonist used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Common side effects of Trulicity include: nausea,
http://www.rxlist.com/trulicity-side-effects-drug-center.htm
It is unknown whether Trulicity causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1), and Nonclinical Toxicology (13.1)].
https://www.drugs.com/pro/trulicity.html
The recommended dose is 1.5 mg once weekly. For potentially vulnerable populations, such as patients ≥ 75 years, 0.75 mg once weekly can be considered as a starting dose. When Trulicity is added to existing metformin and/or pioglitazone therapy, the current dose of metformin and/or pioglitazone can be continued.
http://www.medicines.org.uk/emc/medicine/29747
Trulicity is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1)].
https://www.drugs.com/pro/trulicity.html
1] Trulicity is Eli Lilly and Company's once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes. 1] Trulicity is Eli Lilly and Company's (NYSE: LLY) once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.
http://medical-dictionary.thefreedictionary.com/Trulicity
what is trulicity
Trulicity is a human Glucagon-like peptide-1 receptor agonist used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Trulicity is a human GLP-1 receptor agonist used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.